A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy

被引:4
作者
Lee, Jian Lynn [1 ]
Shah, Noraida Mohamed [1 ]
Makmor-Bakry, Mohd [1 ]
Islahudin, Farida [1 ]
Alias, Hamidah [2 ]
Saffian, Shamin Mohd [1 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Qual Management Med, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia
[2] Univ Kebangsaan Malaysia, Fac Med, UKM Med Ctr, Dept Pediat, Jalan Yaacob Latif, Bandar Tun Razak 56000, Cheras, Malaysia
关键词
Population pharmacokinetics; Nonlinear mixed-effects modeling; Immunoglobulin G; NONMEM; Pharmacometrics; Primary immunodeficiency; LIQUID INTRAVENOUS IMMUNOGLOBULIN; PRIMARY IMMUNODEFICIENCY DISEASES; LONG-TERM TREATMENT; IMMUNE GLOBULIN; REPLACEMENT THERAPY; GAMMA-GLOBULIN; SAFETY; EFFICACY; 10-PERCENT; PRODUCT;
D O I
10.1016/j.intimp.2021.107721
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Population pharmacokinetics (popPK) using the nonlinear mixed-effect (NLME) modeling approach is an essential tool for guiding dose individualization. Several popPK analyses using the NLME have been conducted to characterize the pharmacokinetics of immunoglobulin G (IgG). Objective: To summarize the current information on popPK of polyclonal IgG therapy. Method: A systematic search was conducted in the PubMed and Web of Science databases from inception to December 2020. Additional relevant studies were also included by reviewing the reference list of the reviewed articles. All popPK studies that employed the NLME modeling approach were included and data were synthesized descriptively. Results: This review included seven studies. Most of the popPK models were developed in patients with primary immunodeficiency (PID). IgG pharmacokinetics was described as a two-compartment model in five studies, while it was described as a one-compartment model in two other studies. Among all tested covariates, weight was consistently identified as a significant predictor for clearance (CL) of IgG. Whereas, weight and disease type were found to be significant predictors for the volume of distribution in central compartment (Vc). In a typical 70 kg adult, the median estimated values of Vc and CL were 4.04 L and 0.144 L/day, respectively. The between subject variability of Vc was considered large. Only two studies evaluated their models using external data. Conclusions: Seven popPK studies of IgG were found and discussed, with only weight being a significant covariate across all studies. Future studies linking pharmacokinetics with pharmacodynamics in PID and other patient populations are required.
引用
收藏
页数:11
相关论文
共 99 条
[1]   Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? [J].
Abolhassani, Hasssan ;
Asgardoon, Mohammad Hossein ;
Rezaei, Nima ;
Hammarstrom, Lennart ;
Aghamohammadi, Asghar .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (11) :1229-1243
[2]   Between-subject variability: should high be the new normal? [J].
Al-Sallami, Hesham S. ;
Cheah, Song Lim ;
Han, Shiou Yii ;
Liew, Joel ;
Lim, Jin ;
Ng, Mary Anne ;
Solanki, Hayneil ;
Soo, Run Jie ;
Tan, Victoria ;
Duffull, Stephen B. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (11) :1403-1404
[3]   Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels [J].
Anderson, Collin R. ;
Olson, Jared A. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) :285-289
[4]   Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations [J].
Andresen, I ;
Kovarik, JM ;
Spycher, M ;
Bolli, R .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (07) :722-730
[5]  
[Anonymous], 2014, INTRO POPULATION PHA
[6]   Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications [J].
Bensalem, Amina ;
Ternant, David .
CLINICAL PHARMACOKINETICS, 2020, 59 (07) :857-874
[7]   Safety, efficacy, and pharmacokinetics of Flebogamma® 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases [J].
Berger, M ;
Pinciaro, PJ .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (04) :389-396
[8]   A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma® [J].
Berger, Melvin .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :628-633
[9]   Efficacy, Pharmacokinetics, Safety, and Tolerability of FlebogammaA® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency [J].
Berger, Melvin ;
Pinciaro, Paul J. ;
Althaus, Arthur ;
Ballow, Mark ;
Chouksey, Akhilesh ;
Moy, James ;
Ochs, Hans ;
Stein, Mark .
JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (02) :321-329
[10]   Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection [J].
Bonagura, Vincent R. ;
Marchlewski, Robert ;
Cox, Amanda ;
Rosenthal, David W. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (01) :210-212